Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration

Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2014, Pages 179-188

  Brossard, P ^a   Scherz, M ^a   Halabi, A ^b   Maatouk, H ^b   Krause, A ^a   Dingemanse, J ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Clinical Research Services Kiel GmbH   (Germany)

Author keywords

Healthy subjects; Pharmacodynamics; Pharmacokinetics; Ponesimod; S1P1 receptor modulator

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATROPINE; PLACEBO; PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATRIOVENTRICULAR BLOCK; BACKACHE; BLEPHARITIS; CHILL; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; DESENSITIZATION; DIZZINESS; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FACE PAIN; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART DISEASE; HEART FUNCTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPOTENSION; LUNG FUNCTION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MIGRAINE; MONOCYTOSIS; MOUTH EDEMA; MULTIPLE DRUG DOSE; NAUSEA; NECK PAIN; NORMAL HUMAN; PAINFUL BREATHING; PR INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT DISEASE; SINUS BRADYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION;

ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, LYSOSPHINGOLIPID; THIAZOLES; YOUNG ADULT;

EID: 84895738813     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.244     Document Type: Article

References (35)

1. Horga A, Castilló J, Montalban X. Fingolimod for relapsing multiple sclerosis: an update. Expert Opin Pharmacother. 2010;11:1183-1196.
2. Aarthi JJ, Darendeliler MA, Pushparaj PN. Dissecting the role of the S1P/S1PR axis in health and disease. J Dent Res. 2011;90:841-854.
3. Cyster, JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005; 23:127-159.
4. Brinkmann, V. Sphingosine-1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105.
5. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005;309:1735-1739.
6. Chun, J. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2002;54:265-269.
7. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321-354.
8. Gräler MH, Goetzl EJ. The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G-protein-coupled receptors FASEB J. 2004;18:551-553.
9. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282:9082-9089.
10. Verzijl D, Peters SL, Alewijnse AE. Sphingosine-1-phosphate receptors: zooming in on ligand-induced intracellular trafficking and its functional implications. Mol Cells. 2010;29:99-104.
11. Thangada S, Khanna KM, Blaho VA, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med. 2010;207:1475-1483.
12. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J. Med. 2010;362:402-415.
14. Bolli MH, Abele S, Binkert C, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor modulators. J Med Chem. 2010;53:4198-4211.
15. Piali L, Froidevaux S, Hess P, et al. The selective sphingosine 1-phosphate receptor 1 modulator ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011;337:547-556.
16. Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013;76:888-896.
17. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis. 1971;103:57-67.
18. Gough, K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform J. 1995;29:1039-1048.
19. Monolix, User Guide [computer program]. Version 4.2.0; 2012. http://www.lixoft.eu/wp-content/resources/docs/UsersGuide.pdf.
20. Schmouder R, Serra D, Wang Y, et al. FT Y720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006;46:895-904.
21. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073-1083.
22. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167:1035-1047.
23. Poulsen RR, McClaskey CM, Rivkees SC, Wendler CC. The Sphingosine-1-phospate receptor 1 mediates S1P action during cardiac development. BMC Dev Biol. 2011; 11-37.
24. Kovarik JM, Slade A, Riviere GJ, et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol. 2008;66:199-206.
25. Samson K, Health officials launch investigation in deaths of patients taking fingolimod. Neurol Today. 2012;12(4):27-28.
26. Ammit AJ, Hastie AT, Edsall LC, et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J. 2001; 15:1212-1214.
27. Lai WQ, Wong WS, Leung BP. Sphingosine kinase and sphingosine 1-phosphate in asthma. Biosci Rep. 2011;31:145-150.
28. Trifilieff A, Fozard JR. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. J Pharmacol Exp Ther. 2012;342:399-406.
29. Gon Y, Wood MR, Kiosses WB, et al. S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci USA. 2005;102:9270-9275.
30. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006;2:434-441.
31. Oo ML, Chang SH, Thangada S, et al. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest. 2011;121:2290-2300.
32. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140.
33. Young CA. Factors predisposing to the development of multiple sclerosis. QJM. 2011;104:383-386.
34. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FT Y720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004; 44:532-537.
35. Lee JY, Wang Y. Use of a biomarker in exposure-response analysis to support dose selection for fingolimod. CPT Pharmacometrics Syst Pharmacol. 2013 2:e67. doi: 10.1038/psp.2013.44.